Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 268-273

  Gong, Lei ^a   Xiong, Ming ^a   Huang, Zhiyu ^a   Miao, Lulu ^a   Fan, Yun ^a,b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

ECOG PS; Epidermal growth factor receptor tyrosine kinase inhibitors; Icotinib; Leptomeningeal carcinomatosis; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ICOTINIB; ANTINEOPLASTIC AGENT; CROWN ETHER; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; EXON; FEMALE; HUMAN; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEPLETION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; AGED; GENETICS; LUNG TUMOR; MENINGEAL CARCINOMATOSIS; MORTALITY; MUTATION; PATHOLOGY; RETREATMENT; SECONDARY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CROWN ETHERS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; TREATMENT OUTCOME;

EID: 84938748873     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.06.001     Document Type: Article

References (24)

1. Lee Y., Han J.Y., Kim H.T., Yun T., Lee G.K., Kim H.Y., et al. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. J Neurooncol 2013, 115:95-101.
2. Chen A.M., Jahan T.M., Jablons D.M., Garcia J., Larson D.A. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 2007, 109:1668-1675.
3. Riess J.W., Nagpal S., Iv M., Zeineh M., Gubens M.A., Ramchandran K., et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer 2014, 15:202-206.
4. Chamberlain M.C., Kormanik P.A. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol 1997, 54:1364-1368.
5. Kim D.Y., Lee K.W., Yun T., Park S.R., Jung J.Y., Kim D.W., et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003, 33:608-612.
6. Cole B.F., Glantz M.J., Jaeckle K.A., Chamberlain M.C., Mackowiak J.I. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003, 97:3053-3060.
7. Stapleton S.L., Reid J.M., Thompson P.A., Ames M.M., McGovern R.M., McGuffey L., et al. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol 2007, 59:461-466.
8. Kerr J.Z., Berg S.L., Dauser R., Nuchtern J., Egorin M.J., McGuffey L., et al. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol 2001, 47:411-414.
9. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. Spanish Lung Cancer Group in collaboration with Groupe Francais de P-C, Associazione Italiana Oncologia T.
10. Welsh J.W., Komaki R., Amini A., Munsell M.F., Unger W., Allen P.K., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013, 31:895-902.
11. Lee E., Keam B., Kim D.W., Kim T.M., Lee S.H., Chung D.H., et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013, 8:1069-1074.
12. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13:1364-1369.
13. Zhou L., He J., Xiong W., Yu Q. Phase I trial of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases. J Clin Oncol 2014, 32:5s. (suppl; abstr 8110).
14. Palma J.A., Fernandez-Torron R., Esteve-Belloch P., Fontes-Villalba A., Hernandez A., Fernandez-Hidalgo O., et al. Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. Clin Neurol Neurosurg 2013, 115:19-25.
15. Bruna J., Gonzalez L., Miro J., Velasco R., Gil M., Tortosa A. Neuro-oncology unit of the institute of biomedical investigation of B. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 2009, 115:381-389.
16. Le Rhun E., Taillibert S., Chamberlain M.C. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2013, 4:S265-S288.
17. Park J.H., Kim Y.J., Lee J.O., Lee K.W., Kim J.H., Bang S.M., et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer 2012, 76:387-392.
18. Cessot A., Blanchet B., Goldwasser F. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. Ann Oncol 2014, 25:2093-2094.
19. Clarke J.L., Pao W., Wu N., Miller V.A., Lassman A.B. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99:283-286.
20. Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M., et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013, 8:185-191.
21. Zhang Y., Sheng J., Kang S., Fang W., Yan Y., Hu Z., et al. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis. PLOS ONE 2014, 9:e107161.
22. Glantz M.J., Jaeckle K.A., Chamberlain M.C., Phuphanich S., Recht L., Swinnen L.J., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5:3394-3402.
23. Chuang T.Y., Yu C.J., Shih J.Y., Yang P.C., Kuo S.H. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J Formos Med Assoc 2008, 107:851-856.
24. Morris P.G., Reiner A.S., Szenberg O.R., Clarke J.L., Panageas K.S., Perez H.R., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012, 7:382-385.